000130284 001__ 130284
000130284 005__ 20240124152850.0
000130284 0247_ $$2doi$$a10.1016/j.atherosclerosis.2017.06.009
000130284 0248_ $$2sideral$$a99664
000130284 037__ $$aART-2017-99664
000130284 041__ $$aeng
000130284 100__ $$aBea, A.M.
000130284 245__ $$aEffect of intensive LDL cholesterol lowering with PCSK9 monoclonal antibodies on tendon xanthoma regression in familial hypercholesterolemia
000130284 260__ $$c2017
000130284 5060_ $$aAccess copy available to the general public$$fUnrestricted
000130284 5203_ $$aBackground and aims: The effect of LDLc lowering with PCSK9 antibodies on tendon xanthomas (TX) is unknown.
Methods: TX was measured in 24 heterozygous familial hypercholesterolemia (HeFH) cases and in 24 HeFH controls with or without PCSK9 inhibitors for at least one year.
Results: Exposure to PCSK9 inhibitors in cases was 2.96 ± 1.33 years. LDLc decreased 80.8 ± 7.66% in cases and 56.9 ± 11.1% in controls. There was a decrease in maximum (-5.03%) and mean (-5.32%) TX in cases but not in controls (+3.97%, +3.16, respectively, p = 0.01). PCSK9 inhibitor treatment was independently associated with TX reduction.
Conclusion: Addition of a PCSK9 inhibitor to statin and ezetimibe resulted in a greater decrease in LDLc and TX after 3 years of treatment.
000130284 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/IIS16-0114$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/PIE16-00022$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI15-01983
000130284 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000130284 590__ $$a4.467$$b2017
000130284 591__ $$aPERIPHERAL VASCULAR DISEASE$$b9 / 65 = 0.138$$c2017$$dQ1$$eT1
000130284 591__ $$aCARDIAC & CARDIOVASCULAR SYSTEMS$$b34 / 128 = 0.266$$c2017$$dQ2$$eT1
000130284 592__ $$a1.967$$b2017
000130284 593__ $$aCardiology and Cardiovascular Medicine$$c2017$$dQ1
000130284 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000130284 700__ $$0(orcid)0000-0002-1894-1621$$aPerez-Calahorra, S.
000130284 700__ $$aMarco-Benedi, V.
000130284 700__ $$0(orcid)0000-0002-9647-0108$$aLamiquiz-Moneo, I.
000130284 700__ $$0(orcid)0000-0001-9142-0737$$aJarauta, E.$$uUniversidad de Zaragoza
000130284 700__ $$0(orcid)0000-0001-6650-8294$$aMateo Gallego, R.$$uUniversidad de Zaragoza
000130284 700__ $$0(orcid)0000-0001-7043-0952$$aCiveira, F.$$uUniversidad de Zaragoza
000130284 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000130284 773__ $$g263 (2017), 92-96$$pAtherosclerosis$$tAtherosclerosis$$x0021-9150
000130284 8564_ $$s267304$$uhttps://zaguan.unizar.es/record/130284/files/texto_completo.pdf$$yPostprint
000130284 8564_ $$s1148710$$uhttps://zaguan.unizar.es/record/130284/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000130284 909CO $$ooai:zaguan.unizar.es:130284$$particulos$$pdriver
000130284 951__ $$a2024-01-24-14:59:51
000130284 980__ $$aARTICLE